Abstract:Background: Adherens junctions (AJs) facilitate cell-cell contact and contribute to cellular communication as well as signaling under physiological and pathological conditions. Aberrant expression of AJ proteins is frequently observed in human cancers; however, how these factors contribute to tumorigenesis is poorly understood. In addition, for some factors such as α-catenin contradicting data has been described. In this study we aim to decipher how the AJ constituent α-catenin contributes to liver cancer formation. Methods: TCGA data was used to detect transcript changes in 23 human tumor types. For the detection of proteins, liver cancer tissue microarrays were analyzed by immunohistochemistry. Liver cancer cell lines (HLF, Hep3B, HepG2) were used for viability, proliferation, and migration analyses after RNAinterference-mediated gene silencing. To investigate the tumor initiating potential, vectors coding for α-catenin and myristoylated AKT were injected in mice by hydrodynamic gene delivery. A BioID assay combined with mass spectrometry was performed to identify α-catenin binding partners. Results were confirmed by proximity ligation and co-immunoprecipitation assays. Binding of transcriptional regulators at gene promoters was investigated using chromatin-immunoprecipitation. Results: α-catenin mRNA was significantly reduced in many human malignancies (e.g., colon adenocarcinoma). In contrast, elevated α-catenin expression in other cancer entities was associated with poor clinical outcome (e.g., for hepatocellular carcinoma; HCC). In HCC cells, α-catenin was detectable at the membrane as well as cytoplasm where it supported tumor cell proliferation and migration. In vivo, α-catenin facilitated moderate oncogenic properties in conjunction with AKT overexpression. Cytokinesis regulator centrosomal protein 55 (CEP55) was identified as a novel α-catenin-binding protein in the cytoplasm of HCC cells. The physical interaction between α-catenin and CEP55 was associated with CEP55 stabilization. CEP55 was highly expressed in human HCC tissues and its overexpression correlated with poor overall survival and cancer recurrence. Next to the α-catenin-dependent protein stabilization, CEP55 was transcriptionally induced by a complex consisting of TEA domain transcription factors (TEADs), forkhead box M1 (FoxM1), and yes-associated protein (YAP). Surprisingly, CEP55 did not affect HCC cell proliferation but significantly supported migration in conjunction with α-catenin. Conclusion: Migration-supporting CEP55 is induced by two independent mechanisms in HCC cells: stabilization through interaction with the AJ protein α-catenin and transcriptional activation via the FoxM1/TEAD/YAP complex.

αE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway.

Ascl2 Activation by YAP1/KLF5 Ensures the Self-Renewability of Colon Cancer Progenitor Cells

Src Inhibits the Hippo Tumor Suppressor Pathway Through Tyrosine Phosphorylation of Lats1

TEAD Mediates YAP-dependent Gene Induction and Growth Control

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor.

A Coordinated Phosphorylation By Lats And Ck1 Regulates Yap Stability Through Scf Beta-Trcp

Inactivation of Yap Oncoprotein by the Hippo Pathway is Involved in Cell Contact Inhibition and Tissue Growth Control

Cell Detachment Activates the Hippo Pathway Via Cytoskeleton Reorganization to Induce Anoikis

[Yes-associated protein (YAP) promotes invasion and migration of cutaneous squamous cell carcinoma cells by activating the PI3K/AKT pathway]

SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.

Yes-Associated Protein Contributes to the Development of Human Cutaneous Squamous Cell Carcinoma Via Activation of RAS.

SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway

YAP drives cutaneous squamous cell carcinoma formation and progression

Opposing Activities of the R As and H Ippo Pathways Converge on Regulation of YAP Protein Turnover

YAP/TAZ: a promising target for squamous cell carcinoma treatment

Src mediates -adrenergic receptor induced YAP tyrosine phosphorylation

α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration

The Hippo/YAP Pathway Interacts with EGFR Signaling and HPV Oncoproteins to Regulate Cervical Cancer Progression.

Α-Catenin Acetylation is Essential for Its Stability and Blocks Its Tumor Suppressor Effects in Breast Cancer Through Yap1

ANKHD1 Silencing Suppresses the Proliferation, Migration and Invasion of CRC Cells by Inhibiting YAP1-induced Activation of EMT.

The LKB1–TSSK1B axis controls YAP phosphorylation to regulate the Hippo–YAP pathway